The non-coding RNA based classifier identifies urothelial carcinomas harboring less aggressive tumor biology associated with favorable outcomes after radical cystectomy Joep J. de Jong UT Southwestern Urology Sia Daneshmand, M.D. Roger Li Elai Davicioni Decipher by Veracyte doi.org/10.1111/bju.16…

Molecular Subtyping for Predicting Pathological Upstaging and Survival... sciencedirect.com/science/articl… Multi center collaboration thank you Joep J. de Jong USC Urology UT Southwestern Urology UTSA Emory Urology Moffitt Cancer Center Duke Urology Mayo Clinic UW Urology

“Our findings suggest that molecular subtyping information provided by the Decipher Bladder test can help clinicians better identify which patients may benefit from more-intensive treatment with neoadjuvant chemotherapy," says Yair Lotan, MD. UT Southwestern Urology urologytimes.com/view/genomic-s…

backend_ASCOGU25_CHANG_LOTAN_1 urotoday.com/video-lectures… Joep J. de Jong Decipher by Veracyte UT Southwestern Urology looking forward to the next study!

📊 At #EAU25, multiple abstracts showing the clinical performance of our #Decipher tests & independent performance data supporting our #MRD testing platform. investor.veracyte.com/news-releases/… Note regarding forward looking statements: veracyte.com/cautionary-not…

#EAU2025 clinical relevance of upstaging in MIBC Joep J. de Jong rising star in biomarker research

Gene expression signatures of immune infiltration portend differential response to sequential intravesical gemcitabine and docetaxel vs BCG in high-risk #NMIBC. Presentation by Joep J. de Jong. #EAU25 written coverage by Rashid K. Sayyid > bit.ly/4hCtgaX

Ab#4518 ASCO #ASCO25 by Andrea Necchi 👉 bit.ly/43HuZI7👉Ph2 SURE-02 trial of neo-adj SG-pembro --> adj pembro in pts w/ MIBC #bladdercancer 👉clinical CR in ~39% of pts, allowing bladder preservation👇Francesco Montorsi Chiara Mercinelli Valentina Tateo OncoAlert UroToday.com

📢 #ASCO25 | SURE-02 Ph. II | Interim Results – SG + Pembro in CT-ineligible MIBC (n=40): cCR 38.7% (bladder preserved ~40%), ypT≤1 rate 51.6%; G≥3 AEs 12.9%. Luminal/GU tumors show highest ypT0; stromal signature linked to non-response. Insightful work by Andrea Necchi et al.

Could we avoid radical cystectomy in selected pts with MIBC? Is patient-driven decision and research worth pusuing with this goal? #SURE02 was a challenging effort in this direction, enriched by a lot of biomarker signals Journal of Clinical Oncology ASCO UroToday.com OncLive.com Veracyte, Inc.

Biomarkers for gemcitabine docetaxel in non-muscle invasive #BladderCancer. Vignesh Packiam, MD Rutgers Cancer Institute joins Joep J. de Jong Erasmus MC to discuss promising results for non-muscle invasive bladder cancer, with potential biomarkers on the horizon for precision medicine. #WatchNow

First paper out from my lab! 🎉 Thrilled to share our work on molecular profiling of Ta low-grade bladder cancer, published in European Urology Oncology: 🔗sciencedirect.com/science/articl… Many thanks to Joep J. de Jong, Peter Black, and Lars Dyrskjøt! #bladdercancer #genomics #NMIBC #uroonc

Happy to join Elizabeth Plimack MD and UroToday.com in this discussion on our #SURE02 trial and on newer bladder-sparing approaches Chiara Mercinelli Valentina Tateo Antonio Cigliola Brigida Maiorano ASCO Ospedale San Raffaele Università Vita-Salute San Raffaele Elai Davicioni Joep J. de Jong Veracyte, Inc. Foundation Medicine Fondazione AIRC per la ricerca sul cancro associazionepalinuro

In the search for newer immunotherapy-Response biomarkers in muscle-invasive #bladdercancer we could have ER and AR expression. ER signature expression was associated with poorer outcome in #PURE01 trial. Hints for studies with novel ER inhibitors in MIBC. Congrats Valentina Tateo &

Impact of molecular androgen and estrogen response scores on outcomes following neoadjuvant pembrolizumab in muscle-invasive #BladderCancer aacrjournals.org/clincancerres/… This post-hoc analysis of the PURE-01 trial investigated the influence of androgen and estrogen genomic signatures

Biomarkers for gemcitabine docetaxel in non-muscle invasive #BladderCancer. Vignesh Packiam, MD Rutgers Cancer Institute joins Joep J. de Jong Erasmus MC to discuss promising results for non-muscle invasive bladder cancer, with potential biomarkers on the horizon for precision medicine. #WatchNow

Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy aacrjournals.org/clincancerres/… nice work Joep J. de Jong Ewan Gibbs

Molecular characterization of residual muscle-invasive bladder cancer identifies a scar-like transcriptomicprofile with favorable prognosis after neoadjuvant therapy aacrjournals.org/clincancerres/… This study analyzed RNA sequencing data from #BladderCancer patients treated with

⚡️ A new study identifies a scar-like transcriptomic profile in residual muscle-invasive bladder cancer post-neoadjuvant therapy, linked to a favorable prognosis. This molecular signature could help stratify patients after cystectomy. #BladderCancer #Immunotherapy